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Abstract: High health care costs have left millions of people unable to buy health insurance and has 
broadened the state’s responsibility to protect low-income families through Medicaid programs. Increasing 
health care costs have created severe toll on fiscal management of federal and state governments. Prescription 
drugs are a significant part of Michigan’s Medicaid costs.  Due to the economic recession and the downsizing 
of auto sector the number of Medicaid beneficiaries in Michigan has increased over the years. Thus it has 
increased Medicaid prescription drugs program costs at a fast pace, which creates fiscal burden on Michigan 
in administering the program and providing prescription drugs for its beneficiaries. Michigan has 
implemented several strategies for cost containment of Medicaid since 2001. These strategies have brought 
modest results in terms of cost containment in Medicaid prescription drugs program. This study examined 
whether a generic substitution policy of Medicaid prescription drugs in Michigan would be an efficient and 
effective cost-containment strategy. In doing so, it emphasizes three questions: First, will a generic 
substitution policy be an efficient strategy in containing Medicaid prescription drug program costs for 
Michigan? Second, if not in general, are there any “heavily used” brand drugs for which generic substitutes 
are available that can Michigan safely reduce Medicaid costs by implementing a higher use of generic 
substitution, thus saving the state in prescription drug costs through the generic substitution policy? Third, if 
the answer is yes for the two previous questions, then approximately how much money can Michigan save 
per year by implementing the generic substitution policy? This research found generic substitution policy as 
an efficient way in cost containment in Michigan Medicaid prescription drugs program. 
 
INTRODUCTION 
 
The cost of rising health care, especially Medicaid costs, have taken a tremendous toll on the fiscal management of 
the federal and state governments, because of the responsibility of financing the Medicaid program to ensure health 
care for the low-income groups of the population. Currently, states have spent almost 16% of their budget for 
Medicaid, which is the second largest item in the budget for most (Kaiser Foundation, 2010). This responsibility has 
been broadened significantly by the Patient Protection and Affordable Care  Act (P.L. 111-148) commonly known 
as the health care reform bill signed by President Obama on March 23, 2010. In Michigan, due to the effect of the 
recent federal health care reform bill, it is estimated that the Medicaid expansion will add 375,000 individuals to the 
Medicaid program (Angelotti and Fosdick, 2010). Both federal and state governments have launched 
policies/strategies to control health care costs. Thus, and especially in the current economic downturn, Medicaid cost 
containment has become one of the focal points of federal and state governments’ fiscal policy. More and more 
studies are being conducted, searching for reasons for health care cost escalation and ways to contain Medicaid costs 
(James and Bayley, 2006; Delaune and Everett, 2008; Dalen, 2010, Kelly and Fabius, 2010). 
 
Background - Medicaid Prescription Drug Costs in Michigan 
 
In 2007, one and half million Michigan low-income residents received health care coverage through Medicaid at an 
annual cost of $9 billion (Fairgrive and Stauff, 2007). One in every seven  
Michigan people or 15% of the total Michigan population depends on Medicaid. More than 30% of Michigan’s 2.5 
million children were enrolled in Medicaid in 2007. Seventy-five percent of Medicaid recipients are from lower 
income families, including pregnant women, children, and parents or other care-giver relatives (Fairgrive and Stauff,  
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2007). This situation has intensified due to the recent economic recession and especially due to the near-collapse of 
the three Michigan-based American auto giants.  A large portion of the state population has historically been directly 
or indirectly dependent on the auto industry; moreover, employees of the manufacturing sector—such as auto 
industries—received good health care benefits (Fairgrive and Stauff, 2007). 
In recent years, Michigan has implemented various strategies as part of the state’s ongoing cost 
containment efforts. Of all the policies and strategies for cost containment, savings from prescription drugs in 
Medicaid has received significant attention as a potential source due to its potential advantages over any other 
structural or policy adjustment in this regard (Kibicho, 2006).  Michigan has implemented the following four 
specific policies to contain Medicaid prescription drug costs: 1) in February 2002, introducing a preferred drug list 
for Medicaid beneficiaries known as the Michigan preferred product list (MPPL); 2) in February 2003, 
implementing the Michigan Multistate Pooling Agreement (MMSPA), a joint purchasing arrangement with Vermont, 
also known as the National Medicaid Pooling Initiative (NMP); 
3) in November 2003, establishing a maximum allowable cost for pharmacy reimbursement; and 4) in May 2004, 
coordinating a Michigan multi-state purchasing arrangement (Kibicho, 2006). Although these cost-containment 
initiatives contributed a considerable savings, in reality, these cost-savings strategies achieved only modest success 
in limiting the escalation of Medicaid prescription drug expenditures in terms of total state shares (Grabowski, 2008). 
In containing costs of prescription drugs, a generic substitution policy has received considerable attention. 
Research findings show that increases in the use of generic drugs for prescriptions can reduce a significant amount 
of costs for the Medicaid program (DHHS, 2010; OIG, 2006). Additionally, the DHHS (2010) stated that the quality 
of generic drugs is similar to brand-name and non-generic drugs, while generic drugs are priced much less compared 
to brand-name/non-generic drugs (DHHS, 2010; OIG, 2006). In recent times, ten states (Florida, Kentucky, 
Massachusetts, New Jersey, New Mexico, Oregon, Rhode Island, Tennessee, West Virginia and Wyoming) have 
implemented a generic substitution policy for Medicaid prescription drugs (Shrank et al., 2010).  
In the context of Michigan Medicaid prescription drug cost containment, a generic-substitution policy 
becomes a viable option because Michigan has the potential to use more generic substitutions.  A report prepared by 
DHHS determined that in 2004 55% of drugs prescribed to Michigan Medicaid patients were generic (Grabowski, 
2008). According to Cox et al. (2006), the generic fill rate in Michigan was 52.7% in 2006. 2009 data of Center for 
Medicare and Medicaid (CMS) shows that a total of only 66% generic drugs are utilized for Medicaid beneficiaries, 
which, can be considered moderate. According to CMS data 2009, a 1% increase of generic drug use could 
potentially save the Michigan’s state share $4,616,125, and a 5% increase in generic use could save the state share 
over $ 23 million. Based on the CMS estimate Michigan can save nearly $64.5 million a year in Medicaid 
prescription drugs if it can optimize the use of 80% of generic drugs instead of the current 66% use of generic. A 
Lewin Group (2011) report estimated that Michigan can save a net $453.5 million over the next ten years (from 
2012 to 2021) if the Medicaid pharmacy program—including increased amounts of generics in Medicaid 
prescription drug use—was optimally managed. All this previous research and data suggest that Michigan can 
increase generic substitutions at least 14% to 23%  and even more to achieve the maximum limit of using generic 
drugs and thus, can save a significant amount of money from its Medicaid prescription drug expenditures.  
The present study emphasizes two crucial issues related to Medicaid cost containment in Michigan. First, 
this study asks, if implementation of a generic substitution policy be an effective and efficient strategy for 
containing prescription drugs costs in Michigan Medicaid?  Second, if yes, then what amount Michigan can save by 
the generic substitution policy and from which therapeutic classes?  
 
RESEARCH APPROACH, DESIGN AND METHODOLOGY 
The current study uses a cost benefit approach in examining the above-mentioned research issues and to analyze the 
potential savings by a generic substitution policy regarding cost containment of prescription drugs in the Michigan 
Medicaid program. The cost-benefit analysis is “a technique for systematically estimating the efficiency impacts of 
policies” (Weimer and Vining, 2005, p. 380). In the policy context “a particular matching of resources to use is 
efficient if and only if there exist no better alternative allocation of those same resources” (Munger, 2000, p. 32).  In 
other words, efficiency can be defined as an effort to achieve as much public good as possible for the available 
dollars, and accomplish a public goal by using the fewest possible dollars (Fredericson, 1997).  
Despite the criticism of cost benefit analysis in analyzing public policy, arguing that the approach ignores 
issues of fairness, social equity, social justice, and ethics, which are derived from constitutional, political, and 
judicial bases of public administration (Rosenbloom, 1983),  advantage of using cost-benefit analysis in the current 
study is apparent. As Stokey and Zeckhauser (1978) argued “One of the great virtues of benefit-cost approach is that 
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the interests of individuals who are poorly organized or less closely involved are counted…The benefit and cost 
accruing to all—to the highway builders, the environmentalists, the ‘little people,’ the users and providers of 
services, the taxpaying public—will be counted on a dollar-for-dollar basis. Benefit-cost analysis is a methodology 
with which we pursue efficiency and which has the effect of limiting the vagaries of the political process” (p. 151). 
Besides, cost benefit approach works better when policy deals with efficiency measures, as its emphasis is on the 
cost issue of any public policy (Weimer and Vining, 2005).  
 
Assumptions 
 
The current research makes the following assumptions regarding the proposed hypotheses: 
 
1. Generic drugs are similar to single-source or brand drugs in treating diseases.  The reason for this assumption is 
that generic drugs are chemically identical to single-source brand drugs (OIG, 2006). Additionally, the Food and 
Drug Administration (FDA) states that generic drugs are not only therapeutically equivalent to brand drugs but are 
also  
…required to have the same active ingredient and the same strength, dosage form, and route of 
administration as the brand name (or reference) product. In addition, a generic drug must be bioequivalent 
to the brand drug; that is, there must be no significant difference between the generic and brand product in 
the rate or the extent to which the active ingredient is delivered to the patient. There can be some variability 
between brand name and generic drugs, but the FDA puts limits on how much variability is acceptable 
(DHHS, 2010).   
 
2. Pharmacies cannot or will not increase costs of generic drugs to make up for lost profits on single-source brand 
drugs.  
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Figure 1: Model of cost benefit analysis- status quo and mandatory generic substitution policy 
Policy 1 
 Total Yearly  costs 
 total state share  
 Total Savings    
 Savings in per unit 
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prescription   
Policy 1: Status quo 
 
Policy 2: Generic Substitution 
 Costs 
 Savings  
Policy 2 
 Total Yearly  costs 
 total state share  
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Hypothesis 
 
Based on the research questions, the current study examined the following specific hypothesis: 
 
In case of some brand drugs or therapeutic classes Michigan may have the potential to reduce Medicaid prescription 
drug costs by mandating a higher use of generic substitution whenever available by the generic substitution policy.  
By using the cost benefit analysis the current research analyzed the following specific policies regarding Michigan 
Medicaid prescription drug costs:  
 
1) Status quo or the current policy regarding Medicaid prescription drug without mandating generic 
substitution. 
2)  Introducing a new alternative policy regarding Medicaid prescription drugs by mandating generic 
substitution where available.  
3) In analyzing the potential generic substitution policy for Michigan Medicaid prescription drugs, the 
program’s major components of cost and benefit are as follows: yearly costs/expenditures (for sample 
data set) of prescription drugs, total state share of Michigan in prescription drugs reimbursement, and 
potential total savings of Michigan in Medicaid prescription drugs reimbursement. A diagrammatic 
representation of the model is shown in Figure 1. 
 
The main idea is to examine whether a mandatory use of higher percentage of generic drugs in Medicaid 
prescription drugs program can benefit the state of Michigan more than the status quo or existing policy of not 
mandating the use of generic drugs in the Medicaid prescription drug program in terms of cost savings. If an 
alternative policy (policy 2) can achieve more benefits, then it is better than the status quo. 
 
 
DATA COLLECTION METHOD 
The current research uses State Drug Utilization data and CMS 64 Quarterly Expense data provided by the Center 
for Medicaid and Medicare Services (CMS). These data sets are used by Shrank et al. (2008), Shrank et al. (2010), 
and Brill (2011) in analyzing costs and savings issues of state Medicaid programs. For this purpose, data of 1999 
and every other year from 2002 to 2010 have accessed for Michigan.  
By using the descriptive measure of averages, the current research calculates percentage of state share in 
Medicaid, generic utilization rate, generic prescribing rate, average cost of generics, total generic scripts, percent of 
generic scripts dispensed, single-source drugs prescribing rate, average costs of single-source drugs, total single-
source drug scripts, and percent of single-source drug scripts dispensed for Michigan.  
 
DATA ANALYSIS 
The goal of the current research is to examine if Michigan can introduce a generic substitution policy to contain its 
prescription drug costs. In general, a generic substitution policy refers to a policy that mandates the prescription of 
generic drugs when available, instead of brand drugs or single-source drugs, although states have varied ways to 
implement this policy. Although Michigan has improved the use of generic utilization rate over the years, still there 
is scope to increase the current rate of generics in its Medicaid prescription drug program.  One of the crucial issues 
in Medicaid prescription drugs cost containment is that costs of brand drugs include major shares of total 
expenditure of Medicaid prescription drug programs. For example,   
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Table 2: Brand Drugs with Therapeutically Equivalent  (TE) Reimbursed in MI Medicaid: 
Unit, Amount, and Prescription 
 
Year 
MI brand drug unit  
reimbursed with TE 
No. of 
prescriptions for 
Brand drug with 
TE_ 
MI Brand drug 
with TE amount 
reimbursed in $ 
Brand Drug with TE 
reimbursed amount in 
MI  Medicaid in $ 
Non Medicaid 
Brand Drugs 
with TE 
reimbursed 
amount in $ 
1999 96644743.02 72,921,904.31 
2002 88991515.14 1279224 57,326,219.59 11,637,213.74 4,38,818 
2004 91553571.26 1261508 47,645,639.14 12,469,453.9 10,28,217 
2006 30153814.88 386506 16,820,737.41 11,710,460.61 12,37,590 
2008 43394872.2 525216 39,698,035.96 35,228,960.96 44,69,075 
2010 60138530.47 824309 39,790,835.66 35,759,334.02 40,31,501 
Total $274203372.1 
 
 
 
 Table 3: MICHIGAN SAVINGS  
 
 
 
Year 
MI Average 
per unit costs 
of brand 
drug 
MI Average  costs 
of per TE Brand 
pres drug 
MI Average per 
unit costs of 
generic drug 
Avg. costs 
diff between 
TE brand 
and generics 
Cost @ price of avg. 
generic $ 
Savings @ 
generics $ 
1999 0.754536 0.249658 24,128,086 48793818.05 
2002 0.644176 44.8132771 0.332965 44.48031232 29,631,041 27695178.62 
2004 0.520413 37.76879666 0.226987 37.54181012 20,781,428 26864210.73 
2006 0.557831 43.5199904 0.182533 43.33745697 5,504,079 11316658.1 
2008 0.914809 75.58420909 0.218089 75.36611981 9,463,956 30234079.59 
2010 0.661653 48.2717472 0.233959 48.03778815 14,069,953 25720882.39 
 
Total Avg.  
$41.46 
 
$103,578,545 $170624827.5 
     Source: Calculation is based on CMS State Drug Utilization Data 1999-2010  
 
Table 1: MICHIGAN SAMPLE 
 
 
 
Year 
MI_Units 
Reimbursed 
MI_No. of  
Prescriptions 
MI_Amount 
Reimbursed 
MI_Medicaid 
Amount 
Reimbursed $ 
MI_Non-Medicaid 
Amount Reimbursed 
$ 
1999 305816310.7 4749093 205047795.6 0 
2002 579294000.1 9995281 553806427.6 77818723.48 4634298 
2004 719217135.9 12738792 784847037.3 216595625.5 13549157 
2006 304193547.2 5171836 368336406.9 263460846.1 24417343 
2008 233975864.9 3876283 421436081.4 380880959.4 40555122 
2010 650376695.6 11308819 658795004.1 623213699.7 35581304.4 
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approximately 53% brand drugs contained almost 91.5% costs of Medicaid prescription drug programs in Michigan 
in 2008. In 2010, approximately 21% brand drugs accounted for almost 95% costs of Medicaid prescription drug 
programs in Michigan. Thus higher generic substitution policy with various provisions has received significant 
consideration in the Medicaid prescription drug cost containment efforts.  
By employing a descriptive statistics technique, I chose to calculate the simple average of different measures as 
mentioned before related to brand drugs with therapeutic equivalents or generics available in the market at the 
prescription period (Table 2&3). In doing so, first I categorized all reimbursed drugs under the Medicaid 
prescription drugs program into two groups—brand or generic—as State Drug Utilization data or CMS 64 Quarterly 
database do not provide brand or generic classification. Using the corresponding National Drug Code (NDC) of each 
drug provided by the State Drug Utilization database I cross-checked two FDA databases, Old National Drug Code 
Directory and National Drug Code Directory, to determine if a drug is brand or generic.  
After determining the drug category, I selected all brand drugs that had therapeutically equivalent or 
generic available at the time of prescription in Michigan Medicaid prescription drug program. Then, I calculated the 
average unit price of those ‘brand-to- generic’ matches, and then I calculated the price difference between the total 
brand drug dispensed that had the therapeutically equivalent and the price of its generic equivalents, which could be 
the savings. I calculated this savings as the total amount reimbursed and the Medicaid amount reimbursed in sample 
years.  
Research findings reveal that within the sample years of 1999-2010, the Michigan Medicaid prescription 
drug program spent approximately $274 million for brand drugs that had generic or therapeutically equivalent drugs 
available in the prescription period. At the average rate of available generic drugs within the sample years, these 
brand drugs could cost approximately a total of $103.5 million. Thus Michigan Medicaid could save a total of more 
than $170.5 million by prescribing only generics instead of brand drugs.  
From a public policy context, findings of these descriptive statistics appear as valuable. For example, the 
average cost of per unit brand drug was 90 cents in 1999 and $3.88 in 2010, whereas the average costs of per unit 
generic drugs was estimated at 18 cents to 33 cents within 1999-2010. Similarly, average costs of per prescription 
with brand drugs is estimated at $37.75 to $75.58 within 1999-2010, whereas average costs of per generic 
prescription contained therapeutically equivalent generics varied from $11.94 to $20.43 within 1999-2010. Thus 
Michigan Medicaid prescription drug program could save approximately $49million, $28 million, $27 million, $11 
million, $30 million and $25 million  in 1999, 2002,2004,2006, 2008 and 2010 respectively by using generic drugs 
instead of brand drugs used that had generic equivalent available at the time of prescription  
Findings of the descriptive analysis are similar to other recent research findings. Brill (2010) analyzed 2009 
Medicaid data reimbursement of all states for a selected twenty brand drugs and found $271 million in overspending 
in Medicaid prescription drug programs due to the use of brand drugs instead of generic.  
 In quest of the research hypothesis that if there exists any specific “heavily used” brand drugs  where Michigan 
can save costs in prescription drugs, this research identifies ten specific drugs areas of savings. In doing so, this 
research uses Michigan 2010 Medicaid prescription data as the reference. All brand drugs with therapeutically 
equivalent prescribed are identified with total number of units, number of prescriptions, total amount and total 
medical amount. The ten most costly and highly prescribed brand drugs with therapeutic equivalents in the market 
are identified.  For each of these ten brand drugs with therapeutic equivalents actual prescription drug program costs, 
average costs of actual per unit drugs, average costs of actual per prescription for brand drugs with therapeutically 
equivalent drugs; average costs of per generic drug unit in Michigan in 2010 are calculated. Then average costs of 
per unit brand drugs with therapeutically equivalent are calculated at the rate of average per unit generic drug costs, 
and finally savings are calculated by deducting the amount from actual reimbursement costs of brand drugs with the 
therapeutically equivalent and calculated amount at the rate of average per unit generic drug costs. Then the total 
amount of savings are calculated by adding savings of all ten brand drugs with therapeutically equivalent. 
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FDA 
Approved 
drug name 
Units 
Reimbursed 
 
No. of 
Prescriptions 
Actual Total 
BTE Amount 
Reimbursed 
($) 
Avg. cost 
per unit 
BTE ($) 
Avg. cost 
per 
generic 
unit ($) 
BTE costs @ 
per generic unit 
($) 
Avg. BTE 
cost per 
prescription  
@ per 
generic unit 
($) 
Savings of 
BTE cost @ 
per unit 
generic ($) 
 
PLAVIX 
839193 
27561 4,443,039.27 5.294419 0.233959 196,336.7874 7.12371784 4,246,702 
PROGRAF 416732.1 3685 2,223,677.36 5.335987 0.233959 97,498.24959 26.458141 2,126,179 
LAMICTAL 374526 4048 1,867,966.3 4.987548 0.233959 87,623.74599 21.64618231 1,780,343 
DURAGESIC 38524 4428 1,743,863.81 45.26695 0.233959 9,013.038321 2.035464842 1,734,851 
ZITHROMAX 1136136 72139 1,623,367.64 1.42885 0.233959 265,809.2489 3.684681641 1,357,558 
RISPERIDON 1620172 30325 1,374,779.71 0.84854 0.233959 379,053.7799 12.49971245 995,725.9 
TOPAMAX 284168.2 2765 1,312,345.86 4.618201 0.233959 66,483.7259 24.04474716 1,245,862 
TRILEPTAL 1375522 4142 1,196,764.6 0.870044 0.233959 321,815.8161 77.69575472 874,948.8 
PULMICORT 190546.1 2155 1,030,490.95 5.408094 0.233959 44,579.97458 20.68676315 985,911 
DEPAKOTE S 547865 4420 947,883.82 1.730141 0.233959 128,177.9732 28.99954145 819,705.8 
Total 6823384 155668 17,764,179.3   1,596,392.34  
 
16,167,787 
 
Source: calculated based on CMS’s ‘State Drug Utilization data’ 2010 
Table 4: Brand drugs with Therapeutically Equivalent Reimbursement in Michigan Prescription Drug 
Program in 2010: Costs and Potential Savings 
 
 Table 4 shows that in 2010, Michigan Medicaid prescription drug programs reimbursed an  estimated total of 
$ 17,764,179.3 for ten most “heavily used” brand drugs, which have generic equivalents. Research findings reveal 
that an average $ 0.23 per unit generic drug price  in 2010 Michigan prescription drug program could save an 
estimated approximately $4.25 ; $2.0; $1.5; $ 2.0; $ 1.0 ,$1.0; $1.0; $1.0; $1.0; and $1.0 million respectively from 
these most reimbursed ten brand drugs such as ‘Plavix’, ‘Prograf’, Lamictal’ ‘Duragesic’ ‘Zithromax’ ‘Risperidon’, 
‘Topamax’, ‘Trileptal’, ‘Pulmicort’ and ‘Depakotes’ as shown in the table. At an average rate of generic, these top 
ten brand drugs could cost approximately only $1.5 million. In other words, 90% costs for these ten drugs could be 
offset by using generics. 
 
FINDINGS, RECOMMENDATIONS AND CONCLUSION 
This research examined if there exist any “heavily used” brand drugs for which generic substitutes are available that 
Michigan can safely reduce Medicaid costs by implementing a higher use of generic substitution, thus saving the 
state share in prescription drug costs through the generic substitution policy? In addition this research also examined 
if the answer is ‘yes’ for the previous question, then approximately what amount can Michigan save per year by 
implementing the generic substitution policy? 
Findings of the research are following: 
1. Brand drugs with therapeutically equivalent that are prescribed could be a potential area of savings. In the 
case of Michigan’s Medicaid prescription drug program, savings could be significant if generic drugs are 
prescribed instead of brand drugs with a therapeutic equivalent.  
2. Research findings reveal that within the sample years of 1999-2010 Michigan Medicaid prescription drug 
program spent $274.20 million for brand drugs that had generic or therapeutically equivalent drugs 
available in prescription period. At the rate of available generic drugs in those respective years these brand 
drugs could cost a total of $103.58 million. Thus, Michigan Medicaid could save a total of $170.62 million 
by prescribing only generics instead of those brand drugs.  
3. The more specific area for potential savings for the Michigan Medicaid prescription drug program could be 
using more generic drugs, instead of prescribing brand drugs such as ‘Plavix’, ‘Prograf’, Lamictal’ 
‘Duragesic’ ‘Zithromax’ ‘Risperidon’, ‘Topamax’, ‘Trileptal’, ‘Pulmicort’ and ‘Depakotes’. These are the 
top ten most expensive brand drugs, which have prescribed in the Michigan Medicaid prescription drugs 
program even though generic therapeutically equivalent available in the market for all these brands. 
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4. Research findings show that an estimated $ 17.5 million was reimbursed for total ten most expensive brand 
drugs in the Michigan Medicaid prescription drug program in 2010, which have generic equivalent. At an 
average rate of generic these top ten brand drugs could cost only $1. 5 million. 
5. Thus, Michigan Medicaid prescription drugs program could save an estimated more than $16 million in 
2010 by only prescribing generic instead of those top ten most expensive drugs. 
 
Thus the current research finds a potential relationship between ‘generic substitution policy’ and Medicaid 
prescription drugs costs. The costs variation between brand drugs and the brand with therapeutic classes reveals an 
opportunity for the Michigan Medicaid program to save a significant amount by implementing ‘generic substitute 
policy.’  
 Figure 2 is a modified schematic representation of figure 1 as shown in page 4. In figure 2, a comparative 
cost benefit analysis is shown between “status quo” or having ‘no generic substitution’ policy and a policy of 
potential generic substitution policy in Michigan Medicaid prescription drugs program.  Based on the findings it 
reveals that a generic substitution policy depicted as policy 2 is more efficient than “status quo” or policy 1 in terms 
of savings or in other words cost and benefit in real monetary term between policy 1 or status quo and policy 2 or 
mandatory generic substitution policy. It shows that Michigan could save over $170.5 million by using 
therapeutically equivalent generics instead of using brand drugs through a mandating a generic substitution policy 
within sample years of 1999-2010. 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
Figure 2: Model of cost benefit analysis in real monetary term- status quo and mandatory 
generic substitution policy 
 
Policy 1 
Total yearly  costs of 
Brand drug with generics  
=$274,203,372 million 
Policy 1: Status quo 
 
Policy 2: Generic Substitution 
 Costs 
 Savings  
Selection of policy
 Policy 2 over policy 1 
(based  on  efficiency  ‐
savings) 
Costs Benefits Policy 
Alternatives 
Selection of 
Policy  
Total Savings    
=N/A 
Total Savings (costs of 
policy 1‐policy 2 for brand 
drug with generic 
availability) 
=$170,624,827.5 million 
Policy 2
Total yearly  costs by 
using therapeutically 
equivalent generics 
=$103,578,544.6 million 
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Cost increase in prescription drugs is a complex phenomenon. Many factors contribute to the cost escalation, 
which includes high cost of research and development, advance treatment, promotional and advertisement costs, 
growing groups of an aging population with more needs for prescription drugs, and higher insurance coverage for 
prescriptions. These factors and many others influence in escalating drug price and its utilization and thus overall 
costs for Medicaid prescription drug programs (Kreling, Mott, and Wiederholt, 2001).Thus, cost containment in 
Medicaid drug programs also needs multifaceted policies and actions. As already mentioned, Medicaid costs have 
appeared as the second largest expenditure for Michigan, and created severe pressure on state and local government. 
In the midst of cost escalation of Medicaid prescription  
drug programs, the Michigan state government must implement appropriate measures to tackle this issue. 
Implementation of a generic substitution policy could be a viable policy option for the state government of Michigan. 
Implementation of a generic substitution policy could be an effective and efficient measure to address the issue.   
In containing costs of the Michigan Medicaid prescription drug program, implementing a generic substitution 
policy has some distinct advantages over any other strategies proposed for controlling Medicaid prescription drug 
programs from a public policy context. For example, implementing a generic substitution policy does not need to 
make huge fundamental structural change such as creating a new bureau for Medicaid cost control. Implementation 
of a generic substitution policy most probably has the lowest potential as a political challenge for state government 
than any other policy implementation, which includes such huge numbers of beneficiaries (Kibicho, 2006). One of 
the most intriguing advantages of implementation of a generic policy is that its outcomes are not uncertain, as some 
other states have already been implementing the same policy for years.   
Thus analysis of this research provides a basis of the implementation of a potential generic substitute policy as 
an efficient approach in containing prescription drugs expenditure in the Michigan Medicaid program.  This research, 
therefore, strongly suggests implementing a generic substitution policy without a prior consent provision for 
Michigan in containing costs of its Medicaid prescription drug program. 
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